arrow
F

Francesco Facchinetti

Dana-Farber Cancer Institute
H指数:34
被引数:3,864

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)

一项关于免疫治疗时代下,临床医生对晚期非小细胞肺癌(NSCLC)及体力状态较差患者的态度与生存结局的前瞻性研究:PICASO(GOIRC-04-2020)。

2025-06-010
PRE
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

MET激酶域激活突变与其他驱动癌基因共发生,并介导非小细胞肺癌对靶向治疗的耐药性

2025-04-020
PRE
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

精准肿瘤学中耐药性解码模型:胆管癌对FGFR抑制剂的获得性耐药

2024-12-011
OAAI
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies

了解和克服FGFR2-Driven恶性肿瘤对选择性FGFR抑制剂的耐药性

2024-09-030
OAAI
A prospective study on clinicians' attitudes and survival outcomes for patients with NSCLC and poor performance status in the immunotherapy era: PICASO study (GOIRC-04-2020)

一项关于免疫治疗时代下,临床医生对体力状态较差的非小细胞肺癌(NSCLC)患者的态度及生存结局的前瞻性研究:PICASO研究(GOIRC-04-2020)。

2024-09-010
PRE
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients

癌症患者中TP53和DNA损伤基因的液体活检突变的基因组景观

2024-02-263
OA
Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial Cancer

FGFR驱动的尿路上皮癌对选择性FGFR抑制剂的耐药性

2023-06-2825
OAAI
MatchR a preclinical platform of models resistant to innovative therapies

MatchR是对创新疗法有抵抗力的模型的临床前平台

2023-04-040
PRE
Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
2023-04-040
PRE
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

1671晚期胆道癌患者游离DNA改变的临床表现

2022-12-0165
OA
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
2022-02-1616
OAAI